Pricing Anachronism: Outsourcing the Outcome

1. Introduction: Payers across the global are increasingly looking out for value in drugs and pharma companies are forced to demonstrate significant benefits of their drugs over the over the existing ones. The pharmaceutical industry is waking up to the dawn of regulated pricing with terms like outcome linked pricing and value based pricing etc. With the increased reward for developing orphan drugs and personalized medicines, and ever increasing cost of developing modern biologics, pricing regulations are an anomaly. These changes are forcing pharma industry to lay greater emphasis on outcome research. In this white paper we see the evolution of drug pricing paradigm and discuss in detail the need for outcome research. Towards the end of the whitepaper we will see the impact of pricing regulations in the pharmaceutical procurement and the need for increased penetration of outcome research. We shall also identify how outcome research is being integrated into the existing HEOR supply base and how the buyers and sellers are approaching this growing sub category.